Colleen Reitan Sells 18,000 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Key Points

• Colleen Reitan, a director at Alnylam Pharmaceuticals, sold 18,000 shares of the company's stock for a total of $8.42 million, resulting in a 95.87% decrease in her holdings.
• Alnylam Pharmaceuticals reported earnings of $0.32 per share, exceeding analysts' expectations and generating revenue of $773.69 million for the quarter, which is a 17.3% year-over-year increase.
• Institutional investors have shown increased interest in Alnylam, with several hedge funds significantly raising their positions during the last quarter, resulting in 92.97% of the stock being held by institutional investors.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) Director Colleen Reitan sold 18,000 shares of the firm's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the transaction, the director owned 775 shares in the company, valued at $362,390. This represents a 95.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Alnylam Pharmaceuticals Stock Down 0.2%

Shares of Alnylam Pharmaceuticals stock traded down $0.73 during midday trading on Thursday, reaching $468.58. 1,005,188 shares of the company's stock traded hands, compared to its average volume of 976,267. The company has a market cap of $61.42 billion, a price-to-earnings ratio of -189.71 and a beta of 0.32. The company's 50 day simple moving average is $396.04 and its 200 day simple moving average is $313.80. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals's revenue for the quarter was up 17.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Osaic Holdings Inc. grew its position in Alnylam Pharmaceuticals by 132.5% in the 2nd quarter. Osaic Holdings Inc. now owns 3,787 shares of the biopharmaceutical company's stock worth $1,202,000 after purchasing an additional 2,158 shares during the last quarter. Orion Porfolio Solutions LLC boosted its position in shares of Alnylam Pharmaceuticals by 11.7% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 4,309 shares of the biopharmaceutical company's stock valued at $1,405,000 after acquiring an additional 452 shares in the last quarter. Hudson Bay Capital Management LP boosted its position in shares of Alnylam Pharmaceuticals by 138.4% during the 2nd quarter. Hudson Bay Capital Management LP now owns 15,348 shares of the biopharmaceutical company's stock valued at $5,005,000 after acquiring an additional 55,348 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its position in shares of Alnylam Pharmaceuticals by 8.7% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 91,154 shares of the biopharmaceutical company's stock valued at $29,731,000 after acquiring an additional 7,326 shares in the last quarter. Finally, Ewing Morris & Co. Investment Partners Ltd. acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $470,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of research analyst reports. Morgan Stanley raised their target price on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Jefferies Financial Group raised their target price on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research note on Monday, July 7th. Needham & Company LLC raised their target price on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a "buy" rating in a research note on Thursday, July 31st. Citigroup raised their target price on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. Finally, Barclays raised their target price on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Twenty-three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $421.28.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.